Syncron Recognized as a Major Player in IDC MarketScape for Worldwide AI-Enabled Aftermarket/Service Life-Cycle Management Platforms
STOCKHOLM, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Syncron, a global leader in…
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor,…
